Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis.

PubWeight™: 1.29‹?› | Rank: Top 10%

🔗 View Article (PMID 9854482)

Published in Anticancer Res on January 07, 1999


A Slominski1, R Paus, M C Mihm

Author Affiliations

1: Department of Pathology, Loyola University Medical Center, Maywood, IL.

Articles citing this

Sensing the environment: regulation of local and global homeostasis by the skin's neuroendocrine system. Adv Anat Embryol Cell Biol (2012) 2.99

Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells. Int J Cancer (2009) 1.70

Melanoma resistance: a bright future for academicians and a challenge for patient advocates. Mayo Clin Proc (2014) 1.57

Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma. Hum Pathol (2013) 1.50

Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum Pathol (2011) 1.38

The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways. Arch Biochem Biophys (2014) 1.36

High basal NF-κB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives. Br J Cancer (2011) 1.35

Current concepts of metastasis in melanoma. Expert Rev Dermatol (2008) 1.34

Neuroendocrine activity of the melanocyte. Exp Dermatol (2009) 1.12

Expression of the vitamin D-activating enzyme 1α-hydroxylase (CYP27B1) decreases during melanoma progression. Hum Pathol (2012) 1.09

On the role of the corticotropin-releasing hormone signalling system in the aetiology of inflammatory skin disorders. Br J Dermatol (2009) 1.02

Emerging role of alternative splicing of CRF1 receptor in CRF signaling. Acta Biochim Pol (2010) 0.97

Melanin content in melanoma metastases affects the outcome of radiotherapy. Oncotarget (2016) 0.94

Putative role of HIF transcriptional activity in melanocytes and melanoma biology. Dermatoendocrinol (2013) 0.92

The role of constitutively activated STAT3 in B16 melanoma cells. Int J Interferon Cytokine Mediat Res (2010) 0.91

Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma. Proc Natl Acad Sci U S A (2006) 0.90

Signaling Pathways in Melanogenesis. Int J Mol Sci (2016) 0.87

St John's Wort (Hypericum perforatum L.) photomedicine: hypericin-photodynamic therapy induces metastatic melanoma cell death. PLoS One (2014) 0.87

High-resolution magic angle spinning nuclear magnetic resonance analysis of metabolic changes in melanoma cells after induction of melanogenesis. Anal Biochem (2008) 0.84

RORα and RORγ expression inversely correlates with human melanoma progression. Oncotarget (2016) 0.79

Antitumor effects of vitamin D analogs on hamster and mouse melanoma cell lines in relation to melanin pigmentation. Int J Mol Sci (2015) 0.79

Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice. PLoS One (2015) 0.77

HGF/SF increases number of skin melanocytes but does not alter quality or quantity of follicular melanogenesis. PLoS One (2013) 0.76

Efficient Percutaneous Delivery of the Antimelanogenic Agent Glabridin Using Cationic Amphiphilic Chitosan Micelles. PLoS One (2016) 0.75

Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. Lab Invest (2017) 0.75

Whole Body Melanoma Transcriptome Response in Medaka. PLoS One (2015) 0.75

Proanthocyanidins Extracted from Rhododendron pulchrum Leaves as Source of Tyrosinase Inhibitors: Structure, Activity, and Mechanism. PLoS One (2015) 0.75

Articles by these authors

(truncated to the top 100)

The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res (1969) 13.27

A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages. J Invest Dermatol (2001) 6.12

Sonic hedgehog signaling is essential for hair development. Curr Biol (1998) 5.58

Controls of hair follicle cycling. Physiol Rev (2001) 5.49

Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (1996) 4.46

Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol (2000) 3.42

Noggin is a mesenchymally derived stimulator of hair-follicle induction. Nat Cell Biol (1999) 2.99

Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev (2000) 2.98

GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol (2000) 2.86

Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med (1973) 2.75

Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68

The classification of malignant melanoma and its histologic reporting. Cancer (1973) 2.67

Nonfamilial cutaneous melanoma incidence in women associated with sun exposure before 20 years of age. Pediatrics (1989) 2.61

Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol (1999) 2.50

Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol (1975) 2.36

Melanoma in children. N Engl J Med (1995) 2.35

Benign cutaneous adnexal tumors with combined folliculosebaceous, apocrine, and eccrine differentiation. Clinicopathologic and immunohistochemical study of eight cases. Am J Dermatopathol (1996) 2.30

Interleukin-15 protects from lethal apoptosis in vivo. Nat Med (1997) 2.22

Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J (2000) 2.09

Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08

Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol (2001) 2.06

Noggin is required for induction of the hair follicle growth phase in postnatal skin. FASEB J (2001) 1.95

Kimura's disease and angiolymphoid hyperplasia with eosinophilia: two distinct histopathological entities. J Cutan Pathol (1987) 1.92

Automatic differentiation of melanoma from melanocytic nevi with multispectral digital dermoscopy: a feasibility study. J Am Acad Dermatol (2001) 1.91

Melanogenesis is coupled to murine anagen: toward new concepts for the role of melanocytes and the regulation of melanogenesis in hair growth. J Invest Dermatol (1993) 1.88

Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus. Plast Reconstr Surg (1981) 1.86

Dermal dendritic melanocytic proliferations: an update. Histopathology (2004) 1.84

Analysis of apoptosis during hair follicle regression (catagen) Am J Pathol (1997) 1.82

Narrower margins for clinical stage I malignant melanoma. N Engl J Med (1982) 1.82

Primary melanoma of the skin: recognition and management. J Am Acad Dermatol (1980) 1.82

A new immunologic marker for human Langerhans cells. N Engl J Med (1981) 1.79

A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol (2001) 1.77

Melasma: a clinical, light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol (1981) 1.76

Graying: gerontobiology of the hair follicle pigmentary unit. Exp Gerontol (2001) 1.75

Basophilic leukocytes in allergic contact dermatitis. J Exp Med (1972) 1.75

Rejection of first-set skin allografts in man. the microvasculature is the critical target of the immune response. J Exp Med (1979) 1.74

Characterization of Langerhans cells by the use of monoclonal antibodies. Lab Invest (1981) 1.73

Prognostic factors for melanoma patients with lesions 0.76 - 1.69 mm in thickness. An appraisal of "thin" level IV lesions. Ann Surg (1982) 1.72

Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood (1999) 1.71

Dysplastic melanocytic nevi: a reproducible histologic definition emphasizing cellular morphology. Mod Pathol (1989) 1.71

Pilomatrix carcinoma or calcifying epitheliocarcinoma of Malherbe: a case report and review of literature. Cancer (1980) 1.70

Morphology of delayed-type hypersensitivity reactions in man. II. Ultrastructural alterations affecting the microvasculature and the tissue mast cells. Lab Invest (1976) 1.70

Morphology of delayed type hypersensitivity reactions in man. I. Quantitative description of the inflammatory response. Lab Invest (1974) 1.68

Lentigo maligna and lentigo-maligna melanoma. Am J Pathol (1969) 1.68

Squamoid eccrine ductal carcinoma. Histopathology (1997) 1.67

The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med (1971) 1.65

What are melanocytes really doing all day long...? Exp Dermatol (2009) 1.65

Retracted Death deflected: IL-15 inhibits TNF-alpha-mediated apoptosis in fibroblasts by TRAF2 recruitment to the IL-15Ralpha chain. FASEB J (1999) 1.60

Studies on the cellular origin of neurothekeoma: clinical, light microscopic, immunohistochemical, and ultrastructural observations. J Am Acad Dermatol (1991) 1.59

Detection of proopiomelanocortin-derived antigens in normal and pathologic human skin. J Lab Clin Med (1993) 1.58

Melanocytes as "sensory" and regulatory cells in the epidermis. J Theor Biol (1993) 1.55

Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organization Melanoma Programme. Hum Pathol (1991) 1.54

Control of murine hair follicle regression (catagen) by TGF-beta1 in vivo. FASEB J (2000) 1.48

Bullous dermatosis of hemodialysis. Ann Intern Med (1975) 1.47

Marginal zone lymphoma (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) of skin and subcutaneous tissue: a study of 15 patients. Am J Surg Pathol (1996) 1.45

The natural break points for primary-tumor thickness in clinical Stage I melanoma. N Engl J Med (1981) 1.45

Actin-binding protein expression in benign and malignant melanocytic proliferations. Hum Pathol (1994) 1.44

Origin of cutaneous melanoma in a congenital dysplastic nevus spilus. Arch Dermatol (1990) 1.43

Early melanoma. Histologic terms. Am J Dermatopathol (1991) 1.43

Acral lentiginous melanoma (including in situ melanoma) arising in association with naevocellular naevi. Melanoma Res (1996) 1.42

The human hair follicle immune system: cellular composition and immune privilege. Br J Dermatol (2000) 1.42

Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J (2000) 1.41

Failure of topical estrogen receptor agonists and antagonists to alter murine hair follicle cycling. J Invest Dermatol (1998) 1.40

Topical axitinib suppresses angiogenesis pathways induced by pulsed dye laser. Br J Dermatol (2014) 1.40

The 'melanocyte-keratin' mystery revisited: neither normal human epidermal nor hair follicle melanocytes express keratin 16 or keratin 6 in situ. Br J Dermatol (2009) 1.39

Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol (2008) 1.39

The TGF-beta2 isoform is both a required and sufficient inducer of murine hair follicle morphogenesis. Dev Biol (1999) 1.38

A prognostic model for clinical stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann Surg (1981) 1.38

The role of the hairless (hr) gene in the regulation of hair follicle catagen transformation. Am J Pathol (1999) 1.38

Prognostic factors for patients with clinical stage I melanoma of intermediate thickness (1.51 - 3.39 mm). A conceptual model for tumor growth and metastasis. Ann Surg (1982) 1.38

Abundant production of brain-derived neurotrophic factor by adult visceral epithelia. Implications for paracrine and target-derived Neurotrophic functions. Am J Pathol (1999) 1.37

Role of nerve growth factor in a mouse model of allergic airway inflammation and asthma. Eur J Immunol (1998) 1.37

Congenital melanocytic nevi of the small and garment type. Clinical, histologic, and ultrastructural studies. Hum Pathol (1973) 1.36

Bullous pemphigoid, an ultrastructural study of the inflammatory response: eosinophil, basophil and mast cell granule changes in multiple biopsies from one patient. J Invest Dermatol (1982) 1.35

Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest (1992) 1.34

Alkaline phosphatase activity and localization during the murine hair cycle. Br J Dermatol (1994) 1.34

Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg (1981) 1.34

Molecular and functional aspects of the hairless (hr) gene in laboratory rodents and humans. Exp Dermatol (1998) 1.33

A prognostic model for clinical stage I melanoma of the lower extremity. Location on foot as independent risk factor for recurrent disease. Surgery (1981) 1.33

Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA (1987) 1.30

Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes. Cancer (1981) 1.30

Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis? J Immunol (2000) 1.29

Active hair growth (anagen) is associated with angiogenesis. J Invest Dermatol (2000) 1.29

Melanogenesis during the anagen-catagen-telogen transformation of the murine hair cycle. J Invest Dermatol (1994) 1.27

Neutrophilic eccrine hidradenitis. A distinctive type of neutrophilic dermatosis associated with myelogenous leukemia and chemotherapy. Arch Dermatol (1982) 1.27

Involvement of hepatocyte growth factor/scatter factor and met receptor signaling in hair follicle morphogenesis and cycling. FASEB J (2000) 1.26

Senile hair graying: H2O2-mediated oxidative stress affects human hair color by blunting methionine sulfoxide repair. FASEB J (2009) 1.25

Management of alopecia areata. BMJ (2010) 1.25

Differential expression and activity of melanogenesis-related proteins during induced hair growth in mice. J Invest Dermatol (1991) 1.24

A multivariate analysis of prognostic factors for melanoma patients with lesions greater than or equal to 3.65 mm in thickness. The importance of revealing alternative Cox models. Ann Surg (1982) 1.24

Cellular neurothekeoma. A distinctive variant of neurothekeoma mimicking nevomelanocytic tumors. Am J Surg Pathol (1990) 1.23

T6 is superior to Ia (HLA-DR) as a marker for Langerhans cells and indeterminate cells in normal epidermis: a monoclonal antibody study. J Invest Dermatol (1983) 1.23

E- and P-cadherin expression during murine hair follicle morphogenesis and cycling. Exp Dermatol (1999) 1.22

Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol (1982) 1.21

Characterization of functional vanilloid receptors expressed by mast cells. Blood (1998) 1.21

Retracted The IL-15R alpha chain signals through association with Syk in human B cells. J Immunol (2001) 1.20

Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma. Time-lapse and image analysis. Am J Pathol (1991) 1.20

The human sunburn reaction: histologic and biochemical studies. J Am Acad Dermatol (1981) 1.20

Hair cycle-dependent plasticity of skin and hair follicle innervation in normal murine skin. J Comp Neurol (1997) 1.20

T cell subsets and Langerhans cells in lichen planus: in situ characterization using monoclonal antibodies. Br J Dermatol (1981) 1.19